Stephen Oesterle

Stephen Oesterle is a prominent figure in the medical technology sector, currently serving as a Senior Advisor at Novo Holdings, where he contributes to the Novo Advisory Group (NAG). This group comprises senior industry leaders who assist Novo Holdings in evaluating and monitoring its life science investments. His appointment to this role was announced on October 31, 2023.16

Professional Background

Oesterle has a rich background in both academia and industry. He was a Senior Vice President for Medicine and Technology at Medtronic from 2002 to 2015, where he played a key role in business development and strategic planning, as well as overseeing technology research and development. His tenure at Medtronic included participation in the Executive Committee and involvement in various corporate acquisitions.13

Before his time at Medtronic, Oesterle held academic positions at prestigious institutions. He served as an Associate Professor of Medicine at Harvard Medical School and directed Invasive Cardiology Services at Massachusetts General Hospital. He also led interventional cardiology programs at Stanford University and Good Samaritan Hospital in Los Angeles.134

Education

Oesterle graduated summa cum laude from Harvard University and earned his M.D. from Yale University. He completed his residency at Massachusetts General Hospital and a fellowship in interventional cardiology at Stanford.13

Current Roles

In addition to his role at Novo Holdings, Oesterle is an independent director on several public and private boards, including Baxter International, Paragon 28, and Peijia Medical. He also serves as a venture partner and advisor for multiple private equity firms, including EQT and Patient Square Capital.235

Oesterle's extensive experience and strategic insight in the medical technology field position him as a valuable asset to Novo Holdings and the broader healthcare investment community.